Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 34

1.

Longitudinal functional brain imaging study in early course schizophrenia before and after cognitive enhancement therapy.

Keshavan MS, Eack SM, Prasad KM, Haller CS, Cho RY.

Neuroimage. 2017 May 1;151:55-64. doi: 10.1016/j.neuroimage.2016.11.060. Epub 2016 Nov 26.

PMID:
27894892
2.

Impaired glucose tolerance in first-episode drug-naïve patients with schizophrenia: relationships with clinical phenotypes and cognitive deficits.

Chen DC, Du XD, Yin GZ, Yang KB, Nie Y, Wang N, Li YL, Xiu MH, He SC, Yang FD, Cho RY, Kosten TR, Soares JC, Zhao JP, Zhang XY.

Psychol Med. 2016 Nov;46(15):3219-3230. Epub 2016 Sep 8.

PMID:
27604840
3.

A proof-of-concept, randomized controlled trial of DAR-0100A, a dopamine-1 receptor agonist, for cognitive enhancement in schizophrenia.

Girgis RR, Van Snellenberg JX, Glass A, Kegeles LS, Thompson JL, Wall M, Cho RY, Carter CS, Slifstein M, Abi-Dargham A, Lieberman JA.

J Psychopharmacol. 2016 May;30(5):428-35. doi: 10.1177/0269881116636120. Epub 2016 Mar 10.

PMID:
26966119
4.

Racial disparities during admission to an academic psychiatric hospital in a large urban area.

Hamilton JE, Heads AM, Cho RY, Lane SD, Soares JC.

Compr Psychiatry. 2015 Nov;63:113-22. doi: 10.1016/j.comppsych.2015.08.010. Epub 2015 Sep 4.

PMID:
26555499
5.

In vivo measurement of GABA transmission in healthy subjects and schizophrenia patients.

Frankle WG, Cho RY, Prasad KM, Mason NS, Paris J, Himes ML, Walker C, Lewis DA, Narendran R.

Am J Psychiatry. 2015 Nov 1;172(11):1148-59. doi: 10.1176/appi.ajp.2015.14081031. Epub 2015 Jul 2.

6.

Alterations in cortical network oscillations and parvalbumin neurons in schizophrenia.

Gonzalez-Burgos G, Cho RY, Lewis DA.

Biol Psychiatry. 2015 Jun 15;77(12):1031-40. doi: 10.1016/j.biopsych.2015.03.010. Epub 2015 Mar 17. Review.

7.

Computational study of NMDA conductance and cortical oscillations in schizophrenia.

Kirli KK, Ermentrout GB, Cho RY.

Front Comput Neurosci. 2014 Oct 17;8:133. doi: 10.3389/fncom.2014.00133. eCollection 2014.

8.

Image familiarization sharpens response dynamics of neurons in inferotemporal cortex.

Meyer T, Walker C, Cho RY, Olson CR.

Nat Neurosci. 2014 Oct;17(10):1388-94. doi: 10.1038/nn.3794. Epub 2014 Aug 24.

9.

Cognitive behaviour therapy for command hallucinations.

Cho RY.

Lancet Psychiatry. 2014 Jun;1(1):3-5. doi: 10.1016/S2215-0366(14)70256-1. Epub 2014 Jun 4. No abstract available.

PMID:
26360386
10.

Context specificity of post-error and post-conflict cognitive control adjustments.

Forster SE, Cho RY.

PLoS One. 2014 Mar 6;9(3):e90281. doi: 10.1371/journal.pone.0090281. eCollection 2014.

11.

Development of sensory gamma oscillations and cross-frequency coupling from childhood to early adulthood.

Cho RY, Walker CP, Polizzotto NR, Wozny TA, Fissell C, Chen CM, Lewis DA.

Cereb Cortex. 2015 Jun;25(6):1509-18. doi: 10.1093/cercor/bht341. Epub 2013 Dec 10.

12.

Persistence, diagnostic specificity and genetic liability for context-processing deficits in schizophrenia.

Richard AE, Carter CS, Cohen JD, Cho RY.

Schizophr Res. 2013 Jun;147(1):75-80. doi: 10.1016/j.schres.2013.02.020. Epub 2013 Apr 6.

13.

Dissociating stimulus-set and response-set in the context of task-set switching.

Kieffaber PD, Kruschke JK, Cho RY, Walker PM, Hetrick WP.

J Exp Psychol Hum Percept Perform. 2013 Jun;39(3):700-19. doi: 10.1037/a0029545. Epub 2012 Sep 17.

14.

Dopamine and gamma band synchrony in schizophrenia--insights from computational and empirical studies.

Kömek K, Bard Ermentrout G, Walker CP, Cho RY.

Eur J Neurosci. 2012 Jul;36(2):2146-55. doi: 10.1111/j.1460-9568.2012.08071.x.

15.

[11C]flumazenil binding is increased in a dose-dependent manner with tiagabine-induced elevations in GABA levels.

Frankle WG, Cho RY, Mason NS, Chen CM, Himes M, Walker C, Lewis DA, Mathis CA, Narendran R.

PLoS One. 2012;7(2):e32443. doi: 10.1371/journal.pone.0032443. Epub 2012 Feb 27.

16.

Medication-taking behaviours in young adults with schizophrenia: a pilot study.

Lee H, Kane I, Sereika SM, Cho RY, Jolley CJ.

J Psychiatr Ment Health Nurs. 2011 Jun;18(5):418-24. doi: 10.1111/j.1365-2850.2011.01689.x. Epub 2011 Feb 10.

PMID:
21539687
17.
18.

Neuroprotective effects of cognitive enhancement therapy against gray matter loss in early schizophrenia: results from a 2-year randomized controlled trial.

Eack SM, Hogarty GE, Cho RY, Prasad KM, Greenwald DP, Hogarty SS, Keshavan MS.

Arch Gen Psychiatry. 2010 Jul;67(7):674-82. doi: 10.1001/archgenpsychiatry.2010.63. Epub 2010 May 3.

19.

Assessment of EEG dynamical complexity in Alzheimer's disease using multiscale entropy.

Mizuno T, Takahashi T, Cho RY, Kikuchi M, Murata T, Takahashi K, Wada Y.

Clin Neurophysiol. 2010 Sep;121(9):1438-46. doi: 10.1016/j.clinph.2010.03.025. Epub 2010 Apr 18.

20.

Antipsychotics reverse abnormal EEG complexity in drug-naive schizophrenia: a multiscale entropy analysis.

Takahashi T, Cho RY, Mizuno T, Kikuchi M, Murata T, Takahashi K, Wada Y.

Neuroimage. 2010 May 15;51(1):173-82. doi: 10.1016/j.neuroimage.2010.02.009. Epub 2010 Feb 10.

Supplemental Content

Loading ...
Support Center